While complete Phase 3 data is pending, the trial design incorporates the escalation framework validated in Phase 2 starting at lower doses and escalating over defined intervals to target maintenance doses
Sun Pharma is developing utreglutide, a longacting GLP1 designed to offer metabolic benefits with potentially lower cost and broader accessibility, positioning the company as a future valuedriven challenger to the highpriced injectable and oral franchises of Novo and Lilly
As cysteine and glutathione are scavengers of free radicals (mainly reactive oxygen species (ROS)), they can abrogate the effects of the majority of oxidative or alkylating drugs used in cancer therapy, affording an important resistance mechanism
Li J, Qiu H, Dong Q, Yu H, Piao C, Li Z, et al
Crisol L, Matorras R, Aspichueta F, et al
Our licensed nurses bring everything needed directly to you